scibac
Burlingame
About scibac
SciBac is a developer of biotherapeutics intended to treat antibiotic diseases.The company's technology improves beneficial microorganisms using a patented MERGE platform that uses a type of directed evolution to increase therapeutic efficacy. Its first two therapeutics treat chronic infections in cystic fibrosis for Pseudomonas, Staph, Burkholderia, and NTM.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $4.0M
- Funding stage: Seed
- Last round: Grant (Jul 2019)
- Website: scibac.com
- Phone: (650) 689-5343
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/scibac-36927 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.